32nd EORTC-NCI-AACR on molecular targets and cancer therapeutics goes virtual on Saturday 24 to Sunday 25 October 2020. The opening press conference will be at 17.00 hrs CEST on Tuesday 20 October 2020.
Media can register now for the 32nd
EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics at https://event.eortc.org/ena2020/media/
The virtual Symposium and press conferences are open to bona fide representatives of print and electronic media, and registration is free.
To access the press conferences and to receive official press releases, journalists must register for the Symposium
and be in possession of a valid, recognised press card. Freelance journalists must supply a commissioning letter on headed paper from a recognised news organisation or publication stating that they are being commissioned to write a report for publication. Business cards are NOT acceptable. Full details can be found in the media policy
The opening press conference for the Symposium will take place at 17.00 hrs CEST on Tuesday 20 October
. It will be chaired by the co-chairs of the meeting:
- Emiliano Calvo, START Madrid, Hospital de Madrid Norte Sanchinarro, Madrid, Spain (EORTC),
- William Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts (AACR)
- James Gulley, National Cancer Institute, Bethesda, Maryland (NCI).
During the Symposium around 1,800 international experts in the cancer field will be discussing innovations in drug development, ground-breaking new data, the selection of new targets for anti-cancer drugs, and the impact of new discoveries in molecular biology, in order to improve the survival and quality of life of cancer patients.
The meeting will promote and develop global partnerships in translational research and the 2019 Nobel Prize winner, Sir Peter Ratcliffe
, will deliver the Michel Clavel lecture on Saturday 24 October.
The EORTC-NCI-AACR Symposium is at the forefront of meetings about developing cancer drugs for the future. Understanding the pathways and mechanisms that cause cancer and regulate the biological behaviour of tumour cells has led to the development of numerous new agents, ‘designer’ diagnostics, prognostic tests, ‘smart’ drugs, innovative targets for clinical trials and other entirely new ways of tackling cancer. To bring these developments to patients as quickly and efficiently as possible requires international collaboration, early and optimal exchange of information, good quality translational research, efficient drug development and large prospective clinical trials.
At this Symposium, three of the world’s leading cancer organisations:
- The European Organisation for Research and Treatment of Cancer (EORTC)
- The USA’s National Cancer Institute (NCI)
- The American Association for Cancer Research (AACR)
will join forces in October 2020 to provide a ‘virtual’ platform for presenting recent advances in pre-clinical and clinical research.
More information on the programme is available on the EORTC-NCI-AACR Symposium website